Última actualización 13/11/08Osteoporos Int. 2008 Oct 28. [Epub ahead of print] Cecilia D, Jódar E, Fernández C, Resines C, Hawkins F. One year of once weekly alendronate, when given shortly after the surgical repair of a hip fracture, produces reductions in bone markers and increases proximal femoral bone density. The …Leer más »
Metabolismo Óseo y Mineral
Recent developments in the management of postmenopausal osteoporosis with bisphosphonates: enhanced efficacy by enhanced compliance
Última actualización 13/10/08J Intern Med. 2008 Oct;264(4):315-32. Boonen S, Vanderschueren D, Venken K, Milisen K, Delforge M, Haentjens P. Bisphosphonates are the current mainstay of treatment for postmenopausal osteoporosis. Although daily oral dosing is effective, it is associated with poor compliance, partly because of the pre and postdose fasting and …Leer más »
Última actualización 20/08/08Lancet. 2008 Jul 12;372(9633):155-63. Ralston SH, Langston AL, Reid IR. Paget’s disease of bone is a common disease characterised by focal areas of increased bone turnover, affecting one or several bones throughout the skeleton. Paget’s disease is often asymptomatic but can be associated with bone pain and other …Leer más »
Bolus or weekly zoledronic acid administration does not delay endochondral fracture repair but weekly dosing enhances delays in hard callus remodeling
Última actualización 8/07/08NULL Bone. 2008 Jun 3. [Epub ahead of print] McDonald MM, Dulai S, Godfrey C, Amanat N, Sztynda T, Little DG. Orthopaedic Research and Biotechnology, The Children’s Hospital at Westmead, Westmead Australia; Science Department, University of Technology Sydney, Australia. INTRODUCTION: It has been widely assumed that osteoclasts play …Leer más »
Última actualización 27/06/08NULL Arch Gerontol Geriatr. 2008 Jun 12. [Epub ahead of print] Maugeri D, Russo E, Luca S, Carmelo L, Mamazza G, Sorace R, Rizzotto M, Manuele S, Fiore V, Taverna G, Biagio C, Calitro M. Despite being treated with antiresorptive drugs, the severe osteoporosis (SO) is being considered …Leer más »
Última actualización 15/05/08NULL Arch Intern Med. 2008 Apr 28;168(8):826-31 Heckbert SR, Li G, Cummings SR, Smith NL, Psaty BM. BACKGROUND: A recent publication from the HORIZON (Health Outcomes and Reduced Incidence With Zoledronic Acid Once Yearly) trial in women with postmenopausal osteoporosis reported a higher risk of serious atrial fibrillation …Leer más »
Última actualización 2/05/08NULL Sebba AI. Clin Ther. 2008 Mar;30(3):443-52. Background: Oral bisphosphonates are routinely prescribed for the treatment of postmenopausal osteoporosis. In clinical trials, oral bisphosphonates have been found to increase bone mineral density (BMD) and decrease fracture risk in the majority of the treated population. However, in both clinical …Leer más »
Última actualización 25/03/08NULL Bone. published online 04 March 2008 Rizzoli R. Abstract A potential side effect associated with bisphosphonates, a class of drugs used in the treatment of osteoporosis, Paget’s disease and metastatic bone disease, is osteonecrosis of the jaw (ONJ). The incidence of ONJ in the general population is …Leer más »
An emerging pattern of subtrochanteric stress fractures: A long-term complication of alendronate therapy?
Última actualización 17/03/08NULL Injury. 2008 Feb;39(2):224-31. Epub 2008 Jan 28. Kwek EB, Goh SK, Koh JS, Png MA, Howe TS. BACKGROUND: Subtrochanteric insufficiency fractures in post-menopausal patients have not been commonly reported in the literature. A recent increase in the incidence of such fractures occurring in patients while on alendronate …Leer más »
Does Calcium Supplementation, with or without Vitamin D, Reduce Bone Loss and Fractures in Older Adults?
Última actualización 7/03/08NULL The Medscape Medical Minute George D. Lundberg, MD This is The Medscape Medical Minute. I’m Dr. George Lundberg. We know that men and women over the age of 50 are prone to osteoporosis and increased risk of fractures. A group of investigators from New South Wales in …Leer más »